Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS6B1L
|
|||
| Drug Name |
SGN-LIV1A
|
|||
| Synonyms |
Ladiratuzumab Vedotin
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 2 | [1] | |
| Small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | ||
| Company |
Seattle Genetics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 39 member 6 (SLC39A6) | Target Info | . | [2] |
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.